

Financial Supervision Authority

Current report No. 33/2018

Date prepared: 2018-05-09

Abbreviated name of the issuer:

Mabion S.A.

Subject:

Receipt of the notification of the change in the number of Company's shares

Legal basis

Art. 56 section 1 point 2 of the Act on Public Offering – acquisition or disposal of a significant block of shares

Content of the report:

The Management Board of Mabion S.A. „the Company” hereby informs of the receipt on 9th of May, 2018 from Mr. Maciej Wiczorek a notification of 9th May, 2018 on the change in the number of Company's shares pursuant to Article 69 section 1 point 2 in conjunction with Article 69a of the Act on Public Offering [...] reading as follows:

‘Fulfilling the information obligation arising from Article 69 section 1 point 2 in conjunction with Article 69a of the Act of 29th of July 2005 on Public Offering and Conditions Governing the Introduction of Financial Instruments to Organised Trading and on Public Companies \_Journal of Laws. of 2018 position 512\_, \_’the Law’\_ I announce the decrease in the indirect holding in the total number of votes in Mabion S.A. Company\_’the Company’below the threshold of 15% of the general number of votes in the Company.

1. Date and type of the event, causing the change in share, which is the subject of the notification:

The decrease in the indirect holding in the total number of votes in the Company was caused as a result of the registration on 30th April 2018 of the increase of the Company's share capital by means of issuance of P series shares.

2. The number of shares owned before the change in share and their percentage share in the Company's share capital and the number of votes out of these shares and their percentage share in the general number of votes:

Before the registration of the increase in the Company's capital share, referred to above, I owned indirectly through the companies:

Celon Pharma S.A. total 620 350 of Company's shares that constituted a share of 5,26% in the Company's share capital and 1 113 200 of votes in the General Meeting that constituted 8,33% of shares in the general number of votes, including 492 850 Company's nominative shares, that constituted a share of 4,18% in the Company's share capital and 985 700 General Meeting votes that constituted 7,37% of shares in the general number of votes and 127 500 of Company's ordinary bearer shares that constituted a share of 1,08% in the Company's share capital and 127 500 General Meeting votes that constituted 0,95% of shares in the general number of votes.

Glatton Sp. z o.o. 1 004 526 of Company's ordinary bearer shares that constituted a share of 8,51% in the Company's share capital and 1 004 526 of votes in the General Meeting that constituted 7,51% of shares in the general number of votes.

In total indirectly through Celon Pharma S.A. and Glatton Sp. z o.o. I owned 1 624 876 of Company's shares that constituted a share of 13,77% in the Company's share capital and 2 117 726 General Meeting votes that constituted 15,84% of shares in the general number of votes.

Directly I did not own Company's shares.

3. The total number of presently owned shares and their percentage share in the Company's capital share and the number of votes out of these shares and their percentage share in the general number of shares:

After the registration of the increase in the Company's capital share, referred to above, I own indirectly through the companies:

Celon Pharma S.A. total 620 350 of Company's shares that constitute a share of 4,52% in the Company's share capital and 1 113 200 of votes in the General Meeting that constitute 7,28% of shares in the general number of votes, including 492 850 Company's nominative shares, that constitute a share of 3,59% in the Company's share capital and 985 700 General Meeting votes that constitute 6,45% of shares in the general number of votes and 127 500 of Company's ordinary bearer shares that constitute a share of 0,93% in the Company's share capital and 127 500 General Meeting votes that constitute 0,83% of shares in the general number of votes.

Glatton Sp. z o.o. 1 004 526 of Company's ordinary bearer shares that constitute a share of 7,32% in the Company's share capital and 1 004 526 of votes in the General Meeting that constitute 6,57% of shares in the general number of votes.

In total through Celon Pharma S.A. and Glatton Sp. z o.o. I own 1 624 876 of Company's shares that constitute a share of 11,84% in the Company's share capital and 2 117 726 General Meeting votes that constitute 13,85% of shares in the general number of votes.

Directly I do not own Company's shares.

4. Subsidiaries dependent on the shareholder making the notification, owing the Company's shares:

The only subsidiaries dependent on me owing the Company's shares are Celon Pharma S.A. and Glatton Sp. z o.o.

5. Persons referred to in article 87 section 1 point 3 item c of the Act on Public Offering:  
There is no person referred to in article 87 section 1 point 3 item c of the Act on Public Offering.

6. Number of votes from shares calculated according to article 69b section 2, to the purchase of which is entitled or obliged as the owner of financial instruments, that are referred to in article 69b section 1 point 1, and financial instruments, that are referred to in article 69b section 1 point 2 that are not executed solely by financial settlement, type or name of these instruments, their expiry date and date or time, when the purchase of shares take or may take place:

Does not apply.

7. Number of votes from shares calculated according to article 69b section 3, to which directly or indirectly refer the financial instruments, referred to in article 69b section 1 point 2, type or name of these instruments, and their expiry date:

Does not apply.

8. The total number of votes indicated pursuant to point 2, 6 and 7 and its percentage share in the total number of votes

2 117 726 of votes that constituted 15,84% of shares in the general number of votes.